From $250 · $250 consult · 4.9★ on Trustpilot · All 50 States
850 verified reviews
Premium-concierge GLP-1 with comprehensive metabolic context — the deepest workup in telehealth weight loss, at the appropriate price tier.
Complete the detailed weight-loss-and-metabolic intake — weight history, prior GLP-1 attempts (if any), full medical history, current medications, family history of MTC/MEN-2 (contraindication screen), and goals. Schedule the initial physician consult — Marek's onboarding consult typically runs 30–60 minutes, longer than mass-market GLP-1 telehealth.
Video consult with a licensed physician. Comprehensive lab order issued — fasting glucose, fasting insulin (rare at mass-market), HbA1c, full lipid panel including ApoB and Lp(a), inflammatory markers (hs-CRP), thyroid (TSH + free T4), liver enzymes, kidney function, and leptin where clinically indicated. Local LabCorp or Quest draw site visit; results in 3–5 business days.
Lab review with the prescriber confirms protocol match — including whether semaglutide or tirzepatide is the better fit for your metabolic profile (Marek prescribes both based on lab context). First GLP-1 shipment ships 5–7 days after script approval. Conservative starting dose (semaglutide 0.25mg/week or tirzepatide 2.5mg/week). Async messaging access for protocol questions.
Dose titration to therapeutic range based on response and tolerance. Follow-up labs at 12 weeks then quarterly — tracking weight, metabolic markers (HbA1c trajectory, ApoB direction, insulin sensitivity), and protocol-specific side effects. Average loss at 6 months on therapeutic-dose semaglutide/tirzepatide runs 12–18% of starting body weight at this monitoring depth. Long-term care plan and maintenance-dose conversation begins.
[PeterMD](/online-providers/weight-loss/petermd) and Marek compete on different ends of the GLP-1 telehealth spectrum. PeterMD is the mass-market multi-medication operation ($200–$300/mo, semaglutide + tirzepatide + phentermine all available, async-light intake). Marek is the premium-concierge clinical model ($400–$700+/mo all-in, comprehensive metabolic panel including ApoB/Lp(a)/fasting insulin/leptin, longer prescriber consults, integrated hormone context if relevant). AHF rates Marek 4.4 (weight-loss) and PeterMD 4.3 (weight-loss) — narrow gap reflects PeterMD's flexibility advantage at lower cost vs Marek's clinical depth at higher cost. Pick PeterMD if cost-conscious GLP-1 with medication flexibility fits your case. Pick Marek if you have complex metabolic factors or want sustained concierge-style relationship across the full GLP-1 arc.
[Hims](/online-providers/weight-loss/hims) is the volume-optimized mass-market operation at the lowest entry pricing ($199/mo compounded semaglutide). Marek is the premium-concierge clinical model with comprehensive metabolic monitoring at the higher end of telehealth pricing. The contrast is sharp: Hims optimizes for low-friction, high-volume access to compounded GLP-1; Marek optimizes for clinical depth and integrated metabolic context. AHF rates Marek 4.4 and Hims 4.0 (weight-loss). Pick Hims if compounded semaglutide at the lowest credible price is the priority and your metabolic profile is straightforward. Pick Marek if comprehensive panel work and sustained clinical relationship justify the materially higher monthly cost.
Yes — Marek operates as a licensed U.S. telehealth practice with physicians in each state served. GLP-1 prescribing operates through the same legitimacy infrastructure as their TRT and peptide-therapy lanes: licensed prescribers, real comprehensive lab orders before prescribing, structured monitoring across titration. Marek dispenses both FDA-approved branded GLP-1s where insurance billing or patient preference makes sense, and 503A/503B-compounded semaglutide or tirzepatide where appropriate. The premium pricing reflects the clinical depth model, not corner-cutting on the medication side.
Free consultation. Independently reviewed. Board-certified physicians.
Get Free ConsultationSecure telemedicine · HIPAA compliant · Cancel anytime